Evotec and CHDI Foundation Extend Collaboration to Fight Huntington’s Disease
News Jan 19, 2010
Evotec AG has announced the extension of its collaboration with CHDI Foundation, Inc. (CHDI) through to the end of 2012. The collaboration, which is aimed at finding new treatments for Huntington’s disease and represents one of the largest joint innovation drug discovery CNS alliances within Evotec, will provide Evotec with up to US$ 37.5 million in research funding over the next three years. Evotec has been providing research and innovation support to CHDI since 2006.
“As a proven leader in the field of drug discovery, Evotec continues to be an important strategic partner in our search for effective treatments for Huntington’s disease. Their integrated drug discovery capabilities are helping us advance numerous drug candidates towards the clinic and we look forward to continuing to work with Evotec over the coming years” said Dr Robert Pacifici, Chief Scientific Officer of CHDI.
The extension of this collaboration is a further validation of Evotec’s expertise in CNS drug discovery and development. Evotec will provide a full range of neurological research activities and expertise to CHDI, including integrated biology and chemistry supported by compound and library management, target validation, screening, computational chemistry, in vitro and in vivo PK and protein crystallography. Evotec has made a significant investment to put together an integrated platform to provide drug discovery solutions, especially within the area of neuroscience.
Dr Werner Lanthaler, Chief Executive Officer of Evotec, commented: “We are delighted that CHDI has chosen to further extend our strategic alliance. We view this as an important step in our work with CHDI to develop novel therapies for Huntington’s disease and meet this urgent medical need. At the same time it will allow Evotec to gain further experience in defining the underlying mechanisms of other neurodegenerative diseases.”
Methane Hydrate Formation Studied Using Novel MicroreactorNews
Researchers at the NYU Tandon School of Engineering are using a novel means of studying how methane and water form methane hydrate that allows them to examine discrete steps in the process faster and more efficiently.READ MORE
University of Huddersfield Honorary Award Goes to RSC’s First Woman PresidentNews
The first woman President of the Royal Society of Chemistry, Professor Lesley Yellowlees, will collect an honorary award from University of Huddersfield, which will be presented at the University’s November Award Ceremonies.READ MORE
Drug Discovery Alliance Formed to Help Increase Drug Development Success RateNews
Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development.READ MORE